BRCA1, BRCA2 and PALB2 mRNA Expression as Prognostic Markers in Patients with Early Breast Cancer

被引:1
|
作者
Shehaj, Ina [1 ]
Krajnak, Slavomir [1 ]
Almstedt, Katrin [1 ]
Degirmenci, Yaman [1 ]
Herzog, Sophia [1 ]
Lebrecht, Antje [1 ]
Linz, Valerie Catherine [1 ]
Schwab, Roxana [1 ]
Stewen, Kathrin [1 ]
Brenner, Walburgis [1 ]
Hasenburg, Annette [1 ]
Schmidt, Marcus [1 ]
Heimes, Anne-Sophie [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Obstet & Gynecol, D-55131 Mainz, Germany
基金
英国科研创新办公室;
关键词
mRNA expression; BRCA1; BRCA2; PALB2; metagene; breast cancer; HETEROGENEITY; PROTEIN; IMPACT;
D O I
10.3390/biomedicines12061361
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer (BC) poses a challenge in establishing new treatment strategies and identifying new prognostic and predictive markers due to the extensive genetic heterogeneity of BC. Very few studies have investigated the impact of mRNA expression of these genes on the survival of BC patients. Methods: We examined the impact of the mRNA expression of breast cancer gene type 1 (BRCA1), breast cancer gene type 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) on the metastasis-free survival (MFS) of patients with early BC using microarray gene expression analysis. Results: The study was performed in a cohort of 461 patients with a median age of 62 years at initial diagnosis. The median follow-up time was 147 months. We could show that the lower expression of BRCA1 and BRCA2 is significantly associated with longer MFS (p < 0.050). On the contrary, the lower expression of PALB2 was correlated with a shorter MFS (p = 0.049). Subgroup survival analysis identified the prognostic influence of mRNA expression for BRCA1 among patients with luminal-B-like BC and for BRCA2 and PALB2 in the subset of patients with luminal-A-like BC (p < 0.050). Conclusions: According to our observations, BRCA1, BRCA2, and PALB2 expression might become valuable biomarkers of disease progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago
    Talia Donenberg
    Humayun Ahmed
    Robert Royer
    Shiyu Zhang
    Steven A. Narod
    Sophia George
    Mohammad R. Akbari
    Jameel Ali
    Judith Hurley
    Breast Cancer Research and Treatment, 2016, 159 : 131 - 138
  • [2] A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago
    Donenberg, Talia
    Ahmed, Humayun
    Royer, Robert
    Zhang, Shiyu
    Narod, Steven A.
    George, Sophia
    Akbari, Mohammad R.
    Ali, Jameel
    Hurley, Judith
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (01) : 131 - 138
  • [3] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    P. Wojcik
    M. Jasiowka
    E. Strycharz
    M. Sobol
    D. Hodorowicz-Zaniewska
    P. Skotnicki
    T. Byrski
    P. Blecharz
    E. Marczyk
    I. Cedrych
    J. Jakubowicz
    J. Lubiński
    V. Sopik
    S. Narod
    P. Pierzchalski
    Hereditary Cancer in Clinical Practice, 14
  • [4] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    Wojcik, P.
    Jasiowka, M.
    Strycharz, E.
    Sobol, M.
    Hodorowicz-Zaniewska, D.
    Skotnicki, P.
    Byrski, T.
    Blecharz, P.
    Marczyk, E.
    Cedrych, I.
    Jakubowicz, J.
    Lubinski, J.
    Sopik, V.
    Narod, S.
    Pierzchalski, P.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14
  • [5] PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
    Zhang, Feng
    Ma, Jianglin
    Wu, Jiaxue
    Ye, Lin
    Cai, Hong
    Xia, Bing
    Yu, Xiaochun
    CURRENT BIOLOGY, 2009, 19 (06) : 524 - 529
  • [6] The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives
    A-Yong Cao
    Juan Huang
    Zhen Hu
    Wen-Feng Li
    Zhong-Liang Ma
    Li-Li Tang
    Bin Zhang
    Feng-Xi Su
    Jie Zhou
    Gen-Hong Di
    Kun-Wei Shen
    Jiong Wu
    Jin-Song Lu
    Jian-Min Luo
    Wen-Tao Yuan
    Zhen-Zhou Shen
    Wei Huang
    Zhi-Ming Shao
    Breast Cancer Research and Treatment, 2009, 114 : 457 - 462
  • [7] The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives
    Cao, A-Yong
    Huang, Juan
    Hu, Zhen
    Li, Wen-Feng
    Ma, Zhong-Liang
    Tang, Li-Li
    Zhang, Bin
    Su, Feng-Xi
    Zhou, Jie
    Di, Gen-Hong
    Shen, Kun-Wei
    Wu, Jiong
    Lu, Jin-Song
    Luo, Jian-Min
    Yuan, Wen-Tao
    Shen, Zhen-Zhou
    Huang, Wei
    Shao, Zhi-Ming
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 457 - 462
  • [8] PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response
    Simhadri, Srilatha
    Vincelli, Gabriele
    Huo, Yanying
    Misenko, Sarah
    Foo, Tzeh Keong
    Ahlskog, Johanna
    Sorensen, Claus S.
    Oakley, Gregory G.
    Ganesan, Shridar
    Bunting, Samuel F.
    Xia, Bing
    ONCOGENE, 2019, 38 (10) : 1585 - 1596
  • [9] BRCA1 and BRCA2 in Indian Breast Cancer Patients
    Saxena, Sunita
    Szabo, Csilla I.
    Chopin, Sandrine
    Barjhoux, Laure
    Sinilnikova, Olga
    Lenoir, Gilbert
    Goldgar, David E.
    Bhatanager, Dinesh
    HUMAN MUTATION, 2002, 20 (06) : 473 - 474
  • [10] Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina
    Cerretini, Roxana
    Mercado, Graciela
    Morganstein, Josh
    Schiaffi, Jorge
    Reynoso, Monica
    Montoya, Diana
    Valdez, Rita
    Narod, Steven A.
    Akbari, Mohammad R.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (03) : 629 - 636